for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Imara Inc

IMRA.OQ

Latest Trade

9.97USD

Change

-2.34(-19.01%)

Volume

102,775

Today's Range

8.50

 - 

10.75

52 Week Range

8.50

 - 

61.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
12.31
Open
10.11
Volume
102,775
3M AVG Volume
2.80
Today's High
10.75
Today's Low
8.50
52 Week High
61.00
52 Week Low
8.50
Shares Out (MIL)
17.41
Market Cap (MIL)
173.55
Forward P/E
-2.60
Dividend (Yield %)
--

Latest Developments

More

Imara Inc - Reported Results From Phase 2A Clinical Trial Of Imr-687 In Adult Patients With Sickle Cell Disease

Imara Presents IMR-687 Phase 2A Open Label Extension Case Reports On Two Patients With Sickle Cell Disease At 62nd Ash Annual Meeting And Exposition

Imara Reports Q3 Loss Per Share Of $0.72

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Imara Inc

Imara, Inc. is a clinical-stage biopharmaceutical company. The Company is developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. The Company’s product pipeline include IMR-687, which is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease (SCD), and beta-thalassemia. Its IMR-687 is a selective, small molecule inhibitor of phosphodiesterase-9 (PDE9). The Company is conducting a Phase 2a clinical trial of IMR-687 in adult patients with SCD and a Phase 2b clinical trial for the treatment of patients with beta-thalassemia.

Industry

Biotechnology & Drugs

Contact Info

116 HUNTINGTON AVENUE, 6TH FLOOR

BOSTON, MA

02116

United States

+1.617.2062020

https://imaratx.com/

Executive Leadership

David M. Mott

Independent Chairman of the Board of Director

Rahul D. Ballal

President, Chief Executive Officer, Director

Michael P. Gray

Chief Financial Officer, Chief Operating Officer

Lynette Hopkinson

Senior Vice President - Regulatory

Edward R. Conner

Director

Key Stats

1.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2020(E)

0.0K
EPS (USD)

2020(E)

-3.825
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.83
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up